These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29790455)

  • 1. Successful Management of De Novo Acute Hepatitis B Virus Infection With Entecavir in a Living-Donor Liver Transplant Patient.
    Akbulut S; Harputluoglu M; Yilmaz S
    Exp Clin Transplant; 2018 Oct; 16(5):635-637. PubMed ID: 29790455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience.
    Chang MS; Olsen SK; Pichardo EM; Stiles JB; Rosenthal-Cogan L; Brubaker WD; Guarrera JV; Emond JC; Brown RS
    Transplantation; 2013 Apr; 95(7):960-5. PubMed ID: 23545507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Follow-Up Study on the Renal Protective Efficacy of Telbivudine for Hepatitis B Virus-Infected Taiwanese Patients After Living Donor Liver Transplant.
    Lin KH; Chen YL; Lin PY; Hsieh CE; Ko CJ; Lin CC; Ming YZ
    Exp Clin Transplant; 2017 Feb; 15(1):65-68. PubMed ID: 28004999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
    Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
    Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of de novo hepatitis B with adefovir plus vaccination in recipients of liver transplants from core antibody-positive donors.
    Chang MS; Olsen SK; Pichardo EM; Heese S; Stiles JB; Guarrera JV; Emond JC; Brown RS
    Liver Transpl; 2013 Apr; 19(4):462. PubMed ID: 23536483
    [No Abstract]   [Full Text] [Related]  

  • 7. De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Zhu JJ; Wang SY; Qiu DK
    J Dig Dis; 2013 Aug; 14(8):439-45. PubMed ID: 23638710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft.
    Wang SH; Loh PY; Lin TL; Lin LM; Li WF; Lin YH; Lin CC; Chen CL
    Liver Transpl; 2017 Oct; 23(10):1266-1272. PubMed ID: 28691231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis Among Hepatitis B Core Antibody-positive Deceased-donor Liver Transplant Recipients: Hepatitis B Immunoglobulin Plus Oral Antiviral Agents Versus Antiviral Agents Alone: A Single-center Experience.
    Malik MU; Ucbilek E; Trilianos P; Cameron AM; Gurakar A
    Exp Clin Transplant; 2017 Apr; 15(2):183-188. PubMed ID: 27212251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High prevalence of hepatitis B-antibody loss and a case report of
    Sintusek P; Posuwan N; Wanawongsawad P; Jitraruch S; Poovorawan Y; Chongsrisawat V
    World J Gastroenterol; 2018 Feb; 24(6):752-762. PubMed ID: 29456414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Living-Donor Liver Transplant for Fulminant Hepatitis in a Heart Recipient.
    Yang PC; Ho CM; Chou NK; Wang SS; Wu YM; Ho MC; Hu RH; Lee PH
    Exp Clin Transplant; 2015 Aug; 13(4):369-70. PubMed ID: 24650356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study.
    Wu IT; Hu TH; Hung CH; Lu SN; Wang JH; Lee CM; Chen CH
    Clin Microbiol Infect; 2017 Jul; 23(7):464-469. PubMed ID: 28189857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.
    Yaşar DG; Suyanı E; Özenirler S; Sucak GT
    Transplant Proc; 2013 Mar; 45(2):833-4. PubMed ID: 23498831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China.
    Lei M; Yan LN; Yang JY; Wen TF; Li B; Wang WT; Wu H; Xu MQ; Chen ZY; Wei YG
    World J Gastroenterol; 2018 Dec; 24(48):5525-5536. PubMed ID: 30622380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
    Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
    Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of lamivudine or tenofovir plus intramuscular hepatitis B immunoglobulin in prevention of hepatitis B virus reinfection after liver transplant.
    Nassiri-Toosi M; Kasraianfard A; Ahmadinejad Z; Dashti H; Moini M; Najafi A; Salimi J; Jafarian A
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():127-32. PubMed ID: 25894141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: the ideal post-transplant hepatitis B virus prophylaxis?
    Choudhary NS; Saraf N; Saigal S; Mohanka R; Rastogi A; Goja S; Menon PB; Soin AS
    Transpl Infect Dis; 2015 Jun; 17(3):329-33. PubMed ID: 25682715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of hepatitis B virus reinfection in liver transplant recipients.
    Roche B; Samuel D
    Intervirology; 2014; 57(3-4):196-201. PubMed ID: 25034488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.